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Formulating policy to guide vaccination of women during pregnancy and breastfeeding is 
challenging because the evidence-base to guide decisions is extremely limited.  In the past, ACIP 
has not provided guidance to workgroups on either the process to formulate policy for this 
population or the format and language for recommendations.  As a result, workgroups have taken 
a variety of approaches to considering and presenting the issues, resulting in a diversity of 
recommendations that vary in clarity and underlying rationale. .  The principles presented here 
provide guidance to help standardize both the process of policy formulation and the format and 
language of recommendations for pregnant and breastfeeding women.  All ACIP statements 
about vaccines and other biologics for use in adolescents or adults should include a background 
section on vaccination during pregnancy and breastfeeding and provide explicit pregnancy and 
breastfeeding recommendations using standardized language as outlined below.  To arrive at 
pregnancy and breastfeeding recommendations, ACIP workgroups or subject matter experts 
charged with developing vaccine statements should review the process suggestions outlined 
below.  These suggestions, while similar to the process generally followed by workgroups, focus 
specifically on issues related to pregnancy, breastfeeding and decision making in the absence of 
a strong evidence-base. 
 
1. This document and appendix provide a brief overview of specific issues related to 
vaccination during pregnancy and breastfeeding 
 
2. Guidance for the pregnancy and breastfeeding background section  
a. Title:  “Vaccination of women during pregnancy and breastfeeding” 
b. Scope: This section should address the following core topics with a narrow focus 
on the vaccine product/s in question  
i. Disease burden: pregnant women, fetus, newborns and young infants 
ii. Vaccination during pregnancy 
1. Objective and rationale: (clear statement of the primary 
objective(s): to protect mother and/or fetus and/or neonate and/or 
young infant ) 
2. Immunogenicity data (mother; neonate and young infant if 
available)  
3. Efficacy data (mother; neonate and young infant if available) 
4. Safety data (mother; fetus, neonate and young infant if available) 
5. Pregnancy trimester-specific issues (safety, efficacy, other) 
iii. Vaccination during breastfeeding 
1. Objective and rationale: (clear statement of the primary 
objective(s): to protect mother and/or neonate and/or young infant 
and/or future offspring) 
2. Efficacy 
3. Safety 
4. Timing (eg, immediately post-partum or later in infancy; with 
respect to the infant/childhood vaccine series) 
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iv. Cost-effectiveness (only if there are unique issues related to vaccine use 
during pregnancy/breastfeeding) 
v. Alternatives or adjuncts to vaccination during pregnancy 
vi. Logistics (eg, vaccination record) and coadministration with other 
vaccines 
vii. Areas for future research  (could highlight important, feasible studies that 
would assist vaccine policy decisions) 
c. Length: the section should be short for most vaccine products   
d. Data sources: indicate types of studies including well controlled clinical trials, 
observational studies, reviews of published literature, and unpublished data   
 
3. Guidance for the pregnancy/breastfeeding recommendations  
a. These recommendations should be integrated into the recommendations section of 
the document rather than presented separately (as suggested for the 
pregnancy/breastfeeding background).  Explicit recommendations should be 
provided both for vaccination during pregnancy and during breastfeeding 
b. Recommendations should reference the pregnancy/breastfeeding background 
section for rationale and other details 
c. Pregnancy and breastfeeding recommendations should appear in the “special 
populations” section of the recommendations. If pregnancy or breastfeeding are 
deemed precautions or contraindications, recommendations should instead appear 
in the “precautions/contraindications” section, and the special populations section 
should refer readers to the precautions/ contraindications section. 
d. Recommendations should specify 
i. Precautions/contraindications for the pregnant and breastfeeding 
populations 
ii. Timing of vaccination 
1. During pregnancy: pregnancy trimester 
2. During breastfeeding: any specific time periods to aim for or avoid 
iii. Minimum time period between vaccination and becoming pregnant, if 
vaccination is a precaution or contraindication 
 
4. Guidance on language to reduce unnecessary variation across statements 
a. Pregnancy/breastfeeding background section 
i. For each topic heading listed in 2b, lack of data should be stated explicitly 
where it applies. 
ii. For safety, absence of adequate study/surveillance/follow up should be 
distinguished clearly from absence of adverse events  
b. Recommendations section:  
i. General 
 Distinguish clearly between contraindications and precautions.  ACIP 
definitions are as follows: 
Contraindication: A condition in a recipient that increases the risk for a 
serious adverse reaction. A vaccine will not be administered when a 
contraindication is present 
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Precaution: A condition in a recipient that might increase the risk for a 
serious adverse reaction or that might compromise the ability of the vaccine 
to produce immunity.  Under usual circumstances, vaccination should be 
deferred.  However, vaccination might be indicated because benefits 
outweigh risks 
 
In the context of pregnancy and breastfeeding, serious adverse reaction 
includes maternal, fetal or neonatal serious adverse events linked to the 
vaccine.  Contraindication means that there is direct evidence or strong 
biologic plausibility and suggestive evidence that the risk of severe adverse 
event is elevated for at least one of these groups.  Precaution means there is 
no supporting evidence but there is some biologic plausibility; precaution 
may also mean that there is a lack of data to support safety.   
 
ii. Standard language: Choose which best applies and modify language only 
if necessary 
1. Pregnancy recommendations 
1. “Vaccination of pregnant women is recommended; all 
pregnant women should be vaccinated” 
Illustrative examples:  Inactivated influenza vaccine 
2. “Pregnancy is not a contraindication or precaution to 
vaccination; routine vaccination recommendations should 
be applied to pregnant women” 
Illustrative examples: Tetanus-diphtheria (Td), Hepatitis B, 
Meningococcal polysaccharide  
3. “Pregnancy is a precaution and under normal circumstances 
vaccination should be deferred; vaccine should only be 
given when benefits outweigh risks” 
Illustrative examples:  Hepatitis A , IPV, or yellow fever (in 
case of travel to an area where exposure is likely); rabies (eg, 
after a possible exposure) 
4. “Pregnancy is a contraindication to vaccination; vaccine 
should not be administered to pregnant women. 
Vaccination with contraindicated vaccines during 
pregnancy is not ordinarily a reason for pregnancy 
termination” 
Illustrative examples: MMR, varicella, live-attenuated 
influenza vaccine 
2. Timing of vaccination during pregnancy 
1. “Vaccination can be given at any time during pregnancy” 
2.  “Vaccination should be deferred until X trimester of 
pregnancy unless there is a specific indication for  
vaccination early in pregnancy that outweighs risks” 
3. “Vaccine should not be administered during X trimester of 
pregnancy” 
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4. For vaccines where pregnancy is a contraindication: 
“Women should avoid becoming pregnant until 28 days 
after vaccination” 
i. Note: 28 days is the time period that applies to most 
currently contraindicated vaccines; however if for a 
particular vaccine product there is evidence for a 
shorter or longer time period, the 28 days may be 
modified as needed. 
3. Breastfeeding recommendations   
1.  “Breastfeeding  is not a contraindication or precaution to 
vaccination; routine vaccination recommendations should 
be applied” 
Illustrative examples: Current recommendations appear to 
place all vaccines except smallpox in this category (although 
the language is not clear) 
2. “Breastfeeding is a precaution and under usual 
circumstances vaccination should be deferred; vaccine 
should only be given when benefits outweigh risks” 
3. “Breastfeeding is a contraindication to vaccination; vaccine 
should not be administered to breastfeeding women.” 
Illustrative example: smallpox vaccine 
4. Timing of vaccination during breastfeeding 
1. “Vaccination is recommended before postpartum hospital 
discharge for all women whether or not they intend to 
breastfeed” 
2. “Vaccine may be administered at any time postpartum, for 
all women whether or not they intend to breastfeed” 
3. “Where possible, vaccination of breastfeeding women 
should be deferred until X period postpartum, unless 
benefits outweigh risks” 
4. “For breastfeeding women, vaccine should not be 
administered during X period postpartum” 
 
5. Suggestions to aid policy decision-making in the absence of adequate data  
a. Review any unpublished or pre-licensure data available (eg, from accidental 
vaccinations of pregnant women) 
b. Assess whether there will be adequate data in the future and on what timeline 
c.  Review the decisions of other professional organizations/ other countries and the 
underlying rationale 
d. Review “ACIP precedents” with regards to vaccination during pregnancy and 
breastfeeding 
i. Vaccination during breastfeeding is contraindicated only for smallpox 
vaccine 
ii. Live vaccines pose theoretical concern more often than inactivated 
vaccines 
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iii. When risk of maternal infection is high and risk of a poor outcome is high, 
vaccination is recommended (eg, rabies, yellow fever) 
iv. In the absence of adequate safety and efficacy data, direct protection of 
mother provides a stronger basis than indirect protection of neonate/ 
young infant for a recommendation of vaccination during pregnancy   
v. There is more comfort with second and third trimester vaccination than 
first trimester (not based on safety data, but based on public perception) 
e. Evaluate safety checks in place in case the pregnancy/breastfeeding 
recommendations for the product in question result in unintended adverse 
consequences    
i. Is post-licensure data on safety (passive, or active, or special studies) 
likely to detect important adverse events? 
ii. Are there registries or other sources that would allow for detection of 
safety or efficacy concerns? 
iii. If there are concerns about maternal antibody inhibition of infant response 
to a similar vaccine or fetal antigen tolerance with subsequent diminished 
postnatal responsiveness, is any system in place to monitor those 
outcomes? 
iv. Are there any sentinel events of concern that warrant particular attention? 
 
6.  Suggestions on how to standardize the gathering of expert opinion 
i. Areas of expertise that should be represented in workgroup deliberations: 
1. Disease burden (all relevant populations (eg, pregnant women, 
neonates, young infants) 
2. Vaccine product: efficacy, safety for pregnant women, fetus, 
newborn/infant as relevant 
3. Maternal/neonatal immunology if concerns about maternal antibody 
inhibition of infant immune response to same or related vaccine are 
relevant 
4. Consider: target population representation (eg, pregnant woman; a 
representative of infants who have been affected by the disease in 
question) 
5. Scientific leader from obstetric clinical community 
6. Scientific leader from pediatric clinical community 
7. Consider: inclusion of someone with expertise in health law 
ii. Strategies for obtaining input 
1. If some members are particularly vocal or stifling of free 
conversation, consider solicitation of written input through a 
standard set of key questions from all members 
2. Consider pulling in additional targeted experts if a particular issue 
stands out as complex or controversial 
iii. Suggestion of procedures to follow when expert opinion cannot reach 
consensus 
1. Present pros and cons as options to the full ACIP, with a summary of 
supporting evidence, and let them vote  
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2. Allow the workgroup to draft a dissenting opinion and present both 
positions to ACIP before they vote 
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Appendix: Brief overview of issues related to vaccination during pregnancy and 
breastfeeding 
 
1. Vaccination during pregnancy  
a. Vulnerable populations 
i. Pregnant women 
1. Altered immune response 
2. Increased risk of some infections 
3. Increased risk of severe outcomes (maternal, fetal or both) of some 
infections 
ii. Fetus, newborn, young infant 
1. Immature immune response 
2. Increased risk of some infections 
3. Increased risk of severe outcomes of some infections 
4. Infection sequelae can result in lifelong disability 
b. The promise of vaccination during pregnancy (any or all of the below) 
i. Protection of mother 
ii. Protection of fetus 
iii. Protection of neonate 
iv. Protection of young infant 
v. In the US there are approximately 4 million live births each year 
vi. In the US >98% of women have at least 1 prenatal visit, providing a health 
care opportunity for vaccination 
c. Concerns about vaccination of pregnant women   
i. Lack of data to make evidence-based decisions 
1. No  or limited well-controlled trials to establish efficacy of  vaccines 
in pregnant women or their offspring 
2. No or limited post-licensure studies of efficacy or safety (eg, from 
registries, VAERS, Vaccine Safety Datalink) 
3. No or limited animal data 
4. No or limited data on burden of illness 
o Key aspects of interest: incidence, severity, sequelae, time 
period of most vulnerability to infection 
o Key target populations: pregnant woman, fetus, newborn, 
young infant 
ii. Theoretical concerns about efficacy (woman, fetus, newborn) 
1. Will altered immune status of pregnant woman reduce response to 
vaccine? 
2. Will sufficient maternal antibody be transferred to fetus to confer 
protection (to fetus, newborn)? 
3. Will half life of maternal antibody be sufficient to protect 
fetus/newborn during relevant period of vulnerability? 
iii. Theoretical concerns about safety (woman, fetus, newborn) 
1. Vaccine type 
o Live vaccines (eg, viral antigen) historically have been 
viewed as more risky than inactivated and toxoid vaccines 
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i. There is evidence of fetal vaccinia infection 
following smallpox vaccination during pregnancy 
ii. There is no direct evidence of any live vaccine 
resulting in a fetal or neonatal serious adverse event 
o Even more limited data on newer vaccine types  
i. Unclear that generalizations about live vs. 
inactivated vaccines can be applied to new or future 
vaccine antigen types and technologies 
ii. Unclear that generalizations about live parenteral 
vaccines can be applied to live mucosal vaccines 
2. Additives/adjuvants/preservatives (eg, thimerosal) 
o Limited or no safety data on exposure of pregnant women, 
fetus and newborn to these  
3. Timing of vaccination 
o Safety risks may vary with time period of vaccination 
during pregnancy (eg, early pregnancy vs. late pregnancy; 
immediately post-partum vs. later) 
iv. Concerns about impaired newborn/infant immune response to childhood 
series 
1. Primary concern is inhibition of newborn or infant response to active 
vaccination due to high concentratons of passively acquired maternal 
antibodies 
2. Evidence that transplacental transfer of maternal antibody can 
interfere with infant response to childhood vaccine series  
o naturally-acquired or vaccine-induced maternal measles 
antibody interferes with infant response to measles vaccine 
3. Theoretic concern that vaccination during pregnancy could similarly 
impair response to routine childhood series 
o Extent of inhibition depends on multiple factors (eg, type of 
maternal and infant vaccine antigen, concentration and 
avidity of maternal antibody, timing and doses in infant 
series) 
o Priming of the infant immune system can occur despite 
presence of maternal antibody 
4. In addition to concerns about maternal antibody inhibition of infant 
postnatal responses to infant immunization series, there are also 
theoretical concerns that the fetus could develop antigen tolerance in 
utero which may result in diminished postnatal responsiveness to the 
infant immunization series. 
v. Lack of harmonization with FDA labeled indications (see Table for a 
description of FDA pregnancy categories) 
1. Label subject to federal regulations 
o 21 CFR 201.56 (General) and 201.57 (Specific) 
2. One currently licensed vaccine (HPV) is pregnancy category B  
3. One currently licensed vaccine (anthrax) is pregnancy category D  
4.  All other licensed vaccines are currently labeled as category C  
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vi. Public perception/risk communication  
1. Temporal association between vaccine and adverse pregnancy events 
2.  Principle of avoiding any unnecessary exposures during pregnancy 
vii. Legal liability 
1. National Childhood Vaccine Injury Act 
o If covered vaccine properly prepared and accompanied by 
proper directions and warnings, manufacturer cannot be 
held liable for injuries.  
o Law clearly covers vaccine directly administered to child 
o Statute is silent on in utero transmission (eg, adverse effect 
in fetus whose mother is vaccinated); case law is unclear 
viii. Logistical concerns  
1. Most obstetric offices do not have the infrastructure (eg, proper 
storage refrigerator, tracking of administration documentation 
required by law) to administer vaccines and obstetric providers often 
do not view vaccination as their primary responsibility 
2. There is no good vaccine record keeping system for adult 
vaccination (eg, to avoid problem of repeat vaccination) 
3. Providers who care for pregnant women are often most concerned 
about the woman and fetus and may be less educated/aware about 
infectious risks to the neonate and young infant 
4. Vaccine recommendations for pregnant women have a history of 
lack of clarity 
d. Alternatives or supplements to vaccination during pregnancy: Depending on the 
infection, some or all of the below may be effective as adjuncts or as alternatives 
i. Routine infection control (eg, hand hygiene, respiratory etiquette) 
ii. Vaccination of household contacts of newborns/pregnant women (“cocoon 
strategy” for pertussis and influenza) but limited data on efficacy 
iii. Postpartum vaccination (See section 2 below) 
1. Eg, rubella and Tdap vaccination recommendation 
2. Avoids safety concerns of vaccination during pregnancy 
3. Only confers fetal protection in subsequent pregnancies (assuming 
maternal antibody levels persist at adequate concentrations) 
4. Only confers maternal protection after the time of vaccination (eg, 
misses vulnerable time window of that pregnancy and early 
postpartum period) 
 
2. Vaccination during breastfeeding 
i. Objectives 
1. Protect mother from vaccine-preventable diseases 
2. Indirect protection of neonate/ infant by preventing infection in 
mother (“cocoon strategy”; see 1d) 
3. Confer protection in subsequent pregnancies (eg, rubella) 
4. Transfer of protective antibody to neonate/ infant 
o Antibody in human milk is >90% secretory IgA 
o Offers surface protection in the mouth 
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o Unclear whether offers additional protection (eg, against 
respiratory infection) 
o Transfer of circulatory IgG to infant has not been 
documented 
ii. Concerns 
1. Interruption of breastfeeding (which has known, important benefits) 
2. Interference of antibody transferred via human milk with 
neonate/infant direct response to childhood series 
o A particular issue for orally administered vaccines 
o Evidence from rotavirus and poliovirus vaccines suggest 
this may be overcome by administering >1 dose   
3. Transmission of vaccine virus in the case of live vaccines 
o Evidence from smallpox, MMRV, MMR 
4. Consistency with FDA labels 
o Majority of labels state “Because many drugs are excreted 
in human milk, caution should be exercised when 
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Table.  Food and Drug Administration pregnancy categories*.  Regulation requires that each 
product be classified under one of five pregnancy categories (A, B, C, D, or X), on the basis of 
risk of reproductive and developmental adverse effects or, for certain categories, on the basis of 
such risk weighed against potential benefit.  
Pregnancy category A Adequate and well controlled studies in 
women fail to demonstrate a risk to the fetus in 
the first trimester (and there is no evidence of a 
risk in later trimester), and the possibility of 
fetal harm appears remote. 
Pregnancy category B Animal reproduction studies have failed to 
demonstrate a risk to the fetus and there are no 
adequate and well-controlled studies in 
pregnant women OR Animal studies have 
shown an adverse effect, but adequate and 
well-controlled studies in pregnant women 
have failed to demonstrate a risk to the fetus 
during the first trimester (and there is no 
evidence of risk in later trimesters) 
Pregnancy category C Animal reproduction studies have shown an 
adverse effect on the fetus and there are no 
adequate and well-controlled studies in 
humans, but potential benefits may warrant use 
of the drug in pregnant women despite 
potential risks OR Animal reproduction studies 
have not been conducted and there are no 
adequate and well-controlled studies in humans
Pregnancy category D There is positive evidence of human fetal risk 
based on adverse reaction data from 
investigational or marketing experience or 
studies in humans, but potential benefits may 
warrant use of the drug in pregnant women 
despite potential risks.  
Pregnancy category X Studies in animals or humans have 
demonstrated fetal abnormalities and/or there 
is positive evidence of human fetal risk based 
on adverse reaction data from investigational 
or marketing experience, and the risks involved 
in use of the drug in pregnant women clearly 
outweigh potential benefits.  
*Note: As of January, 2008, FDA is in the process of developing a new pregnancy labeling 
system. This new system is under consideration and has not yet been instituted. 
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This document can be found on the CDC website at: 
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